JP2011507878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507878A5 JP2011507878A5 JP2010539762A JP2010539762A JP2011507878A5 JP 2011507878 A5 JP2011507878 A5 JP 2011507878A5 JP 2010539762 A JP2010539762 A JP 2010539762A JP 2010539762 A JP2010539762 A JP 2010539762A JP 2011507878 A5 JP2011507878 A5 JP 2011507878A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- fused
- alkyl
- aryl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 158
- 125000001072 heteroaryl group Chemical group 0.000 claims description 158
- 125000003118 aryl group Chemical group 0.000 claims description 128
- 125000001188 haloalkyl group Chemical group 0.000 claims description 126
- 229910052736 halogen Inorganic materials 0.000 claims description 97
- 150000002367 halogens Chemical class 0.000 claims description 97
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 85
- 125000001424 substituent group Chemical group 0.000 claims description 80
- 150000002148 esters Chemical class 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 71
- 239000012453 solvate Substances 0.000 claims description 71
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 70
- 229940002612 prodrug Drugs 0.000 claims description 70
- 239000000651 prodrug Substances 0.000 claims description 70
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 47
- 150000002431 hydrogen Chemical class 0.000 claims description 35
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- -1 substituted Chemical class 0.000 claims description 21
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 125000005605 benzo group Chemical group 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 7
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 6
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229940123025 Beta2 integrin antagonist Drugs 0.000 claims description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- 201000009053 Neurodermatitis Diseases 0.000 claims description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 2
- 206010068318 Oropharyngeal discomfort Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 108010016672 Syk Kinase Chemical class 0.000 claims description 2
- 102000000551 Syk Kinase Human genes 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 210000002997 osteoclast Anatomy 0.000 claims description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 150000001721 carbon Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 125000006718 (C3-C7) heterocycloalkenyl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 0 CC(CC12CC1)(C(CC1*)C(CC3)C2C(C)(C=C2)C3=CC2=O)[C@@]1(*)C(CO*)=O Chemical compound CC(CC12CC1)(C(CC1*)C(CC3)C2C(C)(C=C2)C3=CC2=O)[C@@]1(*)C(CO*)=O 0.000 description 1
- MMMJFQYHGDJPPQ-UHFFFAOYSA-N CC1N=NN(C)C1 Chemical compound CC1N=NN(C)C1 MMMJFQYHGDJPPQ-UHFFFAOYSA-N 0.000 description 1
- OJAWOLWHEQUTDE-UHFFFAOYSA-N Cc1c[n](C)nn1 Chemical compound Cc1c[n](C)nn1 OJAWOLWHEQUTDE-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1613507P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/087300 WO2009085879A2 (en) | 2007-12-21 | 2008-12-18 | C20-c21 substituted glucocorticoid receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507878A JP2011507878A (ja) | 2011-03-10 |
| JP2011507878A5 true JP2011507878A5 (enExample) | 2013-01-24 |
Family
ID=40532554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539762A Pending JP2011507878A (ja) | 2007-12-21 | 2008-12-18 | Ｃ２０−ｃ２１置換グルココルチコイド受容体アゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524697B2 (enExample) |
| EP (1) | EP2245042A1 (enExample) |
| JP (1) | JP2011507878A (enExample) |
| CN (1) | CN101970452A (enExample) |
| AR (1) | AR069804A1 (enExample) |
| CA (1) | CA2710149A1 (enExample) |
| CL (1) | CL2008003803A1 (enExample) |
| MX (1) | MX2010007023A (enExample) |
| PE (1) | PE20091525A1 (enExample) |
| TW (1) | TW200944540A (enExample) |
| WO (1) | WO2009085879A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009085880A2 (en) * | 2007-12-21 | 2009-07-09 | Schering Corporation | C-21 thioethers as glucocorticoid receptor agonists |
| RU2420270C2 (ru) * | 2009-07-20 | 2011-06-10 | Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию | Способ лечения рецидивирующего обструктивного бронхита у детей |
| ME01331B (me) * | 2009-09-11 | 2013-12-20 | Chiesi Farm Spa | Derivati izoksazolidina |
| CN103087137A (zh) * | 2011-11-07 | 2013-05-08 | 天津金耀集团有限公司 | 一种21位为硫代烃基的糖皮质激素 |
| UA116622C2 (uk) * | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
| WO2014115167A2 (en) * | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| GB201320091D0 (en) * | 2013-11-14 | 2014-01-01 | Univ Manchester | Selective glucocorticoid receptor ligands |
| ES2829831T3 (es) | 2014-07-23 | 2021-06-02 | Sphaera Pharma Private Ltd | Compuestos 11.beta-hidroxisteroides-4-aza, composiciones y usos de los mismos |
| SG10202001787QA (en) | 2016-06-02 | 2020-04-29 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
| JP7330101B2 (ja) * | 2016-11-08 | 2023-08-21 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ステロイド及びそのタンパク質コンジュゲート |
| WO2018097149A1 (ja) * | 2016-11-24 | 2018-05-31 | 帝人ファーマ株式会社 | スルフィド化合物の製造方法 |
| US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
| CA3070796A1 (en) | 2017-07-24 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Anti-cd8 antibodies and uses thereof |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| RU2020117156A (ru) * | 2017-12-01 | 2022-01-04 | Эббви Инк. | Конъюгаты анти-cd40 антитела и лекарственного средства |
| US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| BR112020013492A2 (pt) | 2018-01-08 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Esteroides e conjugados de anticorpo dos mesmos |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| CN112851743A (zh) * | 2019-11-27 | 2021-05-28 | 重庆华邦胜凯制药有限公司 | 一种氧化杂质的制备方法 |
| CN112876531A (zh) * | 2019-11-29 | 2021-06-01 | 重庆华邦胜凯制药有限公司 | 一种合成地奈德杂质的方法 |
| CR20230451A (es) | 2021-03-23 | 2023-10-11 | Lilly Co Eli | Agonistas del receptor de glucocorticoides |
| AR125079A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Agonistas de receptores de glucocorticoides sustituidos con carboxi |
| TW202304464A (zh) | 2021-03-23 | 2023-02-01 | 美商美國禮來大藥廠 | 新穎糖皮質素受體激動劑 |
| CN114702543B (zh) * | 2022-04-19 | 2023-08-22 | 中国药科大学 | Clascoterone衍生物或其可药用的盐及其制备方法和用途 |
| CN115430392B (zh) * | 2022-08-31 | 2024-04-16 | 江苏诺盟化工有限公司 | 一种苯偶酰的制备方法及专用文丘里喷射器 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1119082A (en) | 1914-03-16 | 1914-12-01 | George A Inman | Protector-plate. |
| US3020275A (en) * | 1960-06-07 | 1962-02-06 | American Cyanamid Co | 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same |
| GB1119082A (en) * | 1966-07-11 | 1968-07-10 | Lepetit Spa | New steroids |
| DE1300940B (de) * | 1966-10-13 | 1969-08-14 | Hoechst Ag | Verfahren zur Herstellung von Tetrahydropyranylaethern von Steroiden |
| US4188385A (en) * | 1978-04-05 | 1980-02-12 | Syntex (U.S.A.) Inc. | Thioetianic acid derivatives |
| US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
| ZA866097B (en) * | 1985-09-12 | 1988-03-30 | Upjohn Co | 20-and 21-amino steroids |
| JP2659279B2 (ja) * | 1993-05-17 | 1997-09-30 | アルコン ラボラトリーズ，インコーポレイテッド | 眼科用抗炎症化合物 |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| CO5310534A1 (es) | 2000-08-05 | 2003-08-29 | Glaxo Group Ltd | Nuevos derivados de androstano anti-inflamatorios |
| AU2002210768B2 (en) * | 2000-11-03 | 2008-01-10 | The University Of Manchester | Selective glucocorticoid receptor agonists |
| RU2008100237A (ru) * | 2005-06-14 | 2009-07-20 | Джилид Сайэнс, Инк. (US) | ОБЩИЕ ПРОЛЕКАРСТВЕННЫЕ ФОРМЫ СТЕРОИДОВ И β-АГОНИСТОВ (ВАРИАНТЫ), ВКЛЮЧАЮЩИЙ ИХ АЭРОЗОЛЬНЫЙ СОСТАВ (ВАРИАНТЫ) И СПОСОБ ПРЕДОТВРАЩЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ЛЕГОЧНЫХ ВОСПАЛЕНИЙ И/ИЛИ БРОНХОСТЕНОЗА С ИХ ПОМОЩЬЮ |
| WO2009085880A2 (en) * | 2007-12-21 | 2009-07-09 | Schering Corporation | C-21 thioethers as glucocorticoid receptor agonists |
| US8916136B2 (en) * | 2010-04-23 | 2014-12-23 | Indian Institute Of Technology Bombay | Glucose biosensor system coupled with an anti-inflammatory module and methods for using the same |
-
2008
- 2008-12-18 AR ARP080105525A patent/AR069804A1/es not_active Application Discontinuation
- 2008-12-18 CL CL2008003803A patent/CL2008003803A1/es unknown
- 2008-12-18 US US12/736,063 patent/US8524697B2/en not_active Expired - Fee Related
- 2008-12-18 CN CN2008801273812A patent/CN101970452A/zh active Pending
- 2008-12-18 JP JP2010539762A patent/JP2011507878A/ja active Pending
- 2008-12-18 TW TW097149406A patent/TW200944540A/zh unknown
- 2008-12-18 WO PCT/US2008/087300 patent/WO2009085879A2/en not_active Ceased
- 2008-12-18 MX MX2010007023A patent/MX2010007023A/es not_active Application Discontinuation
- 2008-12-18 CA CA2710149A patent/CA2710149A1/en not_active Abandoned
- 2008-12-18 PE PE2008002140A patent/PE20091525A1/es not_active Application Discontinuation
- 2008-12-18 EP EP08868864A patent/EP2245042A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507878A5 (enExample) | ||
| JP2011507879A5 (enExample) | ||
| EP2447253B1 (en) | Dihydropyrimidine compounds, preparation methods, pharmaceutical compositions thereof and their use as antiviral agents | |
| ES2222363T3 (es) | Medicamento contra enfermedades viricas. | |
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| US8124632B2 (en) | Alkylsulfonyl-substituted thiazolide compounds | |
| DE60017898T2 (de) | Neuartige heterocyclische carboxamidderivate | |
| JP2009534407A5 (enExample) | ||
| JP2007269797A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| EP2959903B1 (en) | Medicine for treating eye disease | |
| JP2011500638A5 (enExample) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2010501478A5 (enExample) | ||
| JP2008509137A5 (enExample) | ||
| JP2007530601A5 (enExample) | ||
| JP2006512293A5 (enExample) | ||
| JP2019502708A5 (enExample) | ||
| AU2025217289A1 (en) | Pyrrole compounds | |
| CA3178372A1 (en) | Enpp1 modulators and uses thereof | |
| KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
| JP2007518767A5 (enExample) | ||
| CN110612286A (zh) | 氰基取代的稠合双环衍生物及其制备方法和用途 | |
| ZA200407709B (en) | Novel chalcone derivatives and uses thereof. | |
| CN115916345B (zh) | 吡咯并吡啶衍生物及其用途 |